nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—CYP3A4—Bexarotene—hematologic cancer	0.0384	0.0829	CbGbCtD
Sibutramine—CYP3A4—Lomustine—hematologic cancer	0.0357	0.0771	CbGbCtD
Sibutramine—CYP3A4—Busulfan—hematologic cancer	0.0357	0.0771	CbGbCtD
Sibutramine—CYP3A4—Thiotepa—hematologic cancer	0.0318	0.0687	CbGbCtD
Sibutramine—CYP3A4—Methoxsalen—hematologic cancer	0.0248	0.0534	CbGbCtD
Sibutramine—CYP3A4—Bortezomib—hematologic cancer	0.0235	0.0508	CbGbCtD
Sibutramine—CYP3A4—Daunorubicin—hematologic cancer	0.0225	0.0486	CbGbCtD
Sibutramine—CYP3A4—Cytarabine—hematologic cancer	0.0199	0.0429	CbGbCtD
Sibutramine—CYP3A4—Teniposide—hematologic cancer	0.0196	0.0422	CbGbCtD
Sibutramine—CYP3A4—Ifosfamide—hematologic cancer	0.0181	0.039	CbGbCtD
Sibutramine—CYP3A4—Imatinib—hematologic cancer	0.0172	0.0372	CbGbCtD
Sibutramine—CYP3A4—Ruxolitinib—hematologic cancer	0.0162	0.0351	CbGbCtD
Sibutramine—CYP3A4—Nilotinib—hematologic cancer	0.0157	0.0338	CbGbCtD
Sibutramine—CYP3A4—Vinorelbine—hematologic cancer	0.0155	0.0335	CbGbCtD
Sibutramine—CYP3A4—Triamcinolone—hematologic cancer	0.0142	0.0307	CbGbCtD
Sibutramine—CYP3A4—Dasatinib—hematologic cancer	0.0139	0.0299	CbGbCtD
Sibutramine—CYP3A4—Mitoxantrone—hematologic cancer	0.0137	0.0295	CbGbCtD
Sibutramine—CYP3A4—Betamethasone—hematologic cancer	0.0122	0.0263	CbGbCtD
Sibutramine—CYP3A4—Prednisolone—hematologic cancer	0.012	0.026	CbGbCtD
Sibutramine—CYP3A4—Prednisone—hematologic cancer	0.0114	0.0245	CbGbCtD
Sibutramine—CYP3A4—Irinotecan—hematologic cancer	0.0108	0.0233	CbGbCtD
Sibutramine—CYP3A4—Vinblastine—hematologic cancer	0.00958	0.0207	CbGbCtD
Sibutramine—CYP3A4—Vincristine—hematologic cancer	0.00942	0.0203	CbGbCtD
Sibutramine—CYP3A4—Etoposide—hematologic cancer	0.00863	0.0186	CbGbCtD
Sibutramine—CYP3A4—Dexamethasone—hematologic cancer	0.00709	0.0153	CbGbCtD
Sibutramine—CYP3A4—Doxorubicin—hematologic cancer	0.00589	0.0127	CbGbCtD
Sibutramine—SLC6A4—Monoamine Transport—MAPK14—hematologic cancer	0.000303	0.00721	CbGpPWpGaD
Sibutramine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—hematologic cancer	0.000298	0.00709	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.000296	0.00706	CbGpPWpGaD
Sibutramine—CYP3A4—Irinotecan Pathway—ABCG2—hematologic cancer	0.000282	0.00672	CbGpPWpGaD
Sibutramine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	0.000275	0.00656	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—TSC2—hematologic cancer	0.000273	0.00651	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PER1—hematologic cancer	0.000273	0.00651	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—KMT2A—hematologic cancer	0.000273	0.00651	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—UGT1A1—hematologic cancer	0.000266	0.00634	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—MAPK14—hematologic cancer	0.00026	0.0062	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TOP1—hematologic cancer	0.00025	0.00595	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—hematologic cancer	0.000248	0.00591	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—ID2—hematologic cancer	0.000243	0.0058	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TSC2—hematologic cancer	0.000242	0.00577	CbGpPWpGaD
Sibutramine—CYP3A4—Farnesoid X Receptor  Pathway—FGF19—hematologic cancer	0.00024	0.00571	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—MAPK14—hematologic cancer	0.000231	0.00549	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—ABCC3—hematologic cancer	0.000227	0.00541	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—TXN—hematologic cancer	0.000227	0.00541	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—BAD—hematologic cancer	0.000227	0.0054	CbGpPWpGaD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—hematologic cancer	0.00022	0.00523	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000216	0.00513	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—hematologic cancer	0.000215	0.00513	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—UGT1A1—hematologic cancer	0.000214	0.00509	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.000209	0.00497	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.000207	0.00492	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—MAPK14—hematologic cancer	0.000201	0.00479	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000199	0.00474	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—IL1B—hematologic cancer	0.000198	0.00472	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—TXN—hematologic cancer	0.000195	0.00466	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—ABCC3—hematologic cancer	0.000195	0.00466	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—ARNTL—hematologic cancer	0.000195	0.00464	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000191	0.00455	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—UGT1A1—hematologic cancer	0.000184	0.00438	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—NQO1—hematologic cancer	0.000182	0.00434	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	0.000179	0.00425	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—ABCC3—hematologic cancer	0.000173	0.00412	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—TXN—hematologic cancer	0.000173	0.00412	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—IL1B—hematologic cancer	0.000171	0.00406	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.00017	0.00406	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.00017	0.00405	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	0.00017	0.00405	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000169	0.00403	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	0.000168	0.004	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—JUND—hematologic cancer	0.000165	0.00394	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—UGT1A1—hematologic cancer	0.000163	0.00388	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000154	0.00366	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—IL1B—hematologic cancer	0.000151	0.0036	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000151	0.0036	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	0.000151	0.00359	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—CST3—hematologic cancer	0.000149	0.00354	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—NQO1—hematologic cancer	0.000146	0.00349	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—TNF—hematologic cancer	0.000144	0.00343	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PML—hematologic cancer	0.00014	0.00333	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—GSTM1—hematologic cancer	0.00014	0.00333	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000138	0.00328	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HSP90AA1—hematologic cancer	0.000138	0.00328	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—SRC—hematologic cancer	0.000135	0.00321	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—STAT3—hematologic cancer	0.000133	0.00318	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—hematologic cancer	0.000131	0.00313	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	0.000131	0.00312	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000128	0.00305	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TOP2A—hematologic cancer	0.000128	0.00305	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—NQO1—hematologic cancer	0.000126	0.003	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—TNF—hematologic cancer	0.000124	0.00295	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—hematologic cancer	0.000124	0.00294	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000123	0.00293	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTP1—hematologic cancer	0.000122	0.00291	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000122	0.00291	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000122	0.0029	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—EZH2—hematologic cancer	0.000121	0.00289	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HSP90AA1—hematologic cancer	0.000118	0.00282	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—HDAC2—hematologic cancer	0.000115	0.00273	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000114	0.0027	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000113	0.00269	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000113	0.00268	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HGF—hematologic cancer	0.000112	0.00267	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTM1—hematologic cancer	0.000112	0.00267	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—NQO1—hematologic cancer	0.000112	0.00266	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TNF—hematologic cancer	0.00011	0.00261	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	0.000108	0.00258	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000107	0.00255	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000106	0.00254	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000106	0.00253	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTP1—hematologic cancer	0.000105	0.0025	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HSP90AA1—hematologic cancer	0.000105	0.0025	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000104	0.00249	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000103	0.00244	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.0001	0.00239	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	9.98e-05	0.00238	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	9.85e-05	0.00235	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	9.71e-05	0.00231	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—PDGFB—hematologic cancer	9.66e-05	0.0023	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTM1—hematologic cancer	9.65e-05	0.0023	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HGF—hematologic cancer	9.65e-05	0.0023	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC22A1—hematologic cancer	9.43e-05	0.00225	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—NUP98—hematologic cancer	9.42e-05	0.00224	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTP1—hematologic cancer	9.31e-05	0.00222	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—S100A10—hematologic cancer	9.26e-05	0.0022	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	9.13e-05	0.00218	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	9.09e-05	0.00216	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—NUP214—hematologic cancer	9.08e-05	0.00216	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—NCOR1—hematologic cancer	8.69e-05	0.00207	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	8.66e-05	0.00206	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	8.66e-05	0.00206	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—ADCY7—hematologic cancer	8.64e-05	0.00206	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	8.61e-05	0.00205	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	8.6e-05	0.00205	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HGF—hematologic cancer	8.55e-05	0.00204	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTM1—hematologic cancer	8.55e-05	0.00204	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—PDGFB—hematologic cancer	8.3e-05	0.00198	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PRKCG—hematologic cancer	8.3e-05	0.00198	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	8.09e-05	0.00193	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	7.92e-05	0.00189	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SGK1—hematologic cancer	7.92e-05	0.00189	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	7.92e-05	0.00189	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—FAS—hematologic cancer	7.79e-05	0.00186	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CAMK2D—hematologic cancer	7.69e-05	0.00183	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	7.67e-05	0.00183	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CREB1—hematologic cancer	7.53e-05	0.00179	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—PDGFB—hematologic cancer	7.36e-05	0.00175	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL6R—hematologic cancer	7.34e-05	0.00175	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	7.33e-05	0.00175	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	7.22e-05	0.00172	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	7.13e-05	0.0017	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	7.12e-05	0.0017	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP4A—hematologic cancer	7.02e-05	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ANXA2—hematologic cancer	7.02e-05	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SGK1—hematologic cancer	7.02e-05	0.00167	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—CDK4—hematologic cancer	6.86e-05	0.00163	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—PRKCG—hematologic cancer	6.35e-05	0.00151	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	6.32e-05	0.0015	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	6.26e-05	0.00149	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—CREB1—hematologic cancer	6.14e-05	0.00146	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	5.73e-05	0.00136	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—hematologic cancer	5.58e-05	0.00133	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—hematologic cancer	5.57e-05	0.00133	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCC3—hematologic cancer	5.55e-05	0.00132	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—JUN—hematologic cancer	5.41e-05	0.00129	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—NUP98—hematologic cancer	5.4e-05	0.00129	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	5.25e-05	0.00125	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—NUP214—hematologic cancer	5.21e-05	0.00124	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	5.1e-05	0.00122	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	5.07e-05	0.00121	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—EP300—hematologic cancer	4.99e-05	0.00119	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—PRKCG—hematologic cancer	4.86e-05	0.00116	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—NUP98—hematologic cancer	4.79e-05	0.00114	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	4.73e-05	0.00113	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CREB1—hematologic cancer	4.7e-05	0.00112	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	4.65e-05	0.00111	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ADCY7—hematologic cancer	4.65e-05	0.00111	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—BRAF—hematologic cancer	4.64e-05	0.00111	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—NUP214—hematologic cancer	4.61e-05	0.0011	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	4.59e-05	0.00109	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—TGFB1—hematologic cancer	4.58e-05	0.00109	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TFRC—hematologic cancer	4.55e-05	0.00108	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCG2—hematologic cancer	4.52e-05	0.00108	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—JUN—hematologic cancer	4.42e-05	0.00105	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	4.37e-05	0.00104	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	4.31e-05	0.00103	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PTEN—hematologic cancer	4.27e-05	0.00102	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—MAPK8—hematologic cancer	4.18e-05	0.000996	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—EP300—hematologic cancer	4.08e-05	0.000971	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TNF—hematologic cancer	4.05e-05	0.000965	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TFRC—hematologic cancer	4.03e-05	0.00096	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—TGFB1—hematologic cancer	3.93e-05	0.000937	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—ALB—hematologic cancer	3.92e-05	0.000934	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—MDM2—hematologic cancer	3.89e-05	0.000926	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	3.86e-05	0.000919	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CYCS—hematologic cancer	3.82e-05	0.000909	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—MTR—hematologic cancer	3.79e-05	0.000903	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	3.61e-05	0.000859	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CREB1—hematologic cancer	3.6e-05	0.000858	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—BRAF—hematologic cancer	3.56e-05	0.000847	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—TGFB1—hematologic cancer	3.49e-05	0.00083	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—ALB—hematologic cancer	3.47e-05	0.000827	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CYCS—hematologic cancer	3.38e-05	0.000805	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL6—hematologic cancer	3.27e-05	0.000779	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.18e-05	0.000759	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—MDM2—hematologic cancer	2.98e-05	0.00071	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TP53—hematologic cancer	2.92e-05	0.000695	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCB1—hematologic cancer	2.82e-05	0.000672	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—IL6—hematologic cancer	2.67e-05	0.000636	CbGpPWpGaD
Sibutramine—Hyperhidrosis—Prednisone—hematologic cancer	2.56e-05	5.17e-05	CcSEcCtD
Sibutramine—Vision blurred—Methotrexate—hematologic cancer	2.55e-05	5.16e-05	CcSEcCtD
Sibutramine—Rash—Cisplatin—hematologic cancer	2.54e-05	5.13e-05	CcSEcCtD
Sibutramine—Dermatitis—Cisplatin—hematologic cancer	2.54e-05	5.13e-05	CcSEcCtD
Sibutramine—Malnutrition—Epirubicin—hematologic cancer	2.53e-05	5.12e-05	CcSEcCtD
Sibutramine—Diarrhoea—Etoposide—hematologic cancer	2.52e-05	5.1e-05	CcSEcCtD
Sibutramine—Anorexia—Prednisone—hematologic cancer	2.52e-05	5.09e-05	CcSEcCtD
Sibutramine—Eye disorder—Doxorubicin—hematologic cancer	2.52e-05	5.09e-05	CcSEcCtD
Sibutramine—Ill-defined disorder—Methotrexate—hematologic cancer	2.51e-05	5.08e-05	CcSEcCtD
Sibutramine—Tinnitus—Doxorubicin—hematologic cancer	2.51e-05	5.08e-05	CcSEcCtD
Sibutramine—Anaemia—Methotrexate—hematologic cancer	2.5e-05	5.06e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Dexamethasone—hematologic cancer	2.5e-05	5.06e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Betamethasone—hematologic cancer	2.5e-05	5.06e-05	CcSEcCtD
Sibutramine—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	2.5e-05	0.000595	CbGpPWpGaD
Sibutramine—Flatulence—Epirubicin—hematologic cancer	2.5e-05	5.05e-05	CcSEcCtD
Sibutramine—Tension—Epirubicin—hematologic cancer	2.49e-05	5.03e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Betamethasone—hematologic cancer	2.48e-05	5.02e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.48e-05	5.02e-05	CcSEcCtD
Sibutramine—Dysgeusia—Epirubicin—hematologic cancer	2.48e-05	5.02e-05	CcSEcCtD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	2.47e-05	0.000587	CbGpPWpGaD
Sibutramine—Hypersensitivity—Triamcinolone—hematologic cancer	2.47e-05	4.98e-05	CcSEcCtD
Sibutramine—Nervousness—Epirubicin—hematologic cancer	2.46e-05	4.97e-05	CcSEcCtD
Sibutramine—Back pain—Epirubicin—hematologic cancer	2.45e-05	4.95e-05	CcSEcCtD
Sibutramine—Angiopathy—Doxorubicin—hematologic cancer	2.44e-05	4.94e-05	CcSEcCtD
Sibutramine—Malaise—Methotrexate—hematologic cancer	2.44e-05	4.94e-05	CcSEcCtD
Sibutramine—Dizziness—Etoposide—hematologic cancer	2.44e-05	4.93e-05	CcSEcCtD
Sibutramine—Muscle spasms—Epirubicin—hematologic cancer	2.44e-05	4.92e-05	CcSEcCtD
Sibutramine—Immune system disorder—Doxorubicin—hematologic cancer	2.43e-05	4.92e-05	CcSEcCtD
Sibutramine—Vertigo—Methotrexate—hematologic cancer	2.43e-05	4.92e-05	CcSEcCtD
Sibutramine—Leukopenia—Methotrexate—hematologic cancer	2.42e-05	4.9e-05	CcSEcCtD
Sibutramine—Chills—Doxorubicin—hematologic cancer	2.42e-05	4.88e-05	CcSEcCtD
Sibutramine—Urticaria—Dexamethasone—hematologic cancer	2.41e-05	4.88e-05	CcSEcCtD
Sibutramine—Urticaria—Betamethasone—hematologic cancer	2.41e-05	4.88e-05	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.41e-05	4.87e-05	CcSEcCtD
Sibutramine—Dizziness—Prednisolone—hematologic cancer	2.41e-05	4.86e-05	CcSEcCtD
Sibutramine—Arrhythmia—Doxorubicin—hematologic cancer	2.41e-05	4.86e-05	CcSEcCtD
Sibutramine—Asthenia—Triamcinolone—hematologic cancer	2.4e-05	4.85e-05	CcSEcCtD
Sibutramine—Body temperature increased—Betamethasone—hematologic cancer	2.4e-05	4.85e-05	CcSEcCtD
Sibutramine—Abdominal pain—Betamethasone—hematologic cancer	2.4e-05	4.85e-05	CcSEcCtD
Sibutramine—Abdominal pain—Dexamethasone—hematologic cancer	2.4e-05	4.85e-05	CcSEcCtD
Sibutramine—Body temperature increased—Dexamethasone—hematologic cancer	2.4e-05	4.85e-05	CcSEcCtD
Sibutramine—Nausea—Cisplatin—hematologic cancer	2.39e-05	4.83e-05	CcSEcCtD
Sibutramine—Insomnia—Prednisone—hematologic cancer	2.39e-05	4.83e-05	CcSEcCtD
Sibutramine—Vision blurred—Epirubicin—hematologic cancer	2.39e-05	4.83e-05	CcSEcCtD
Sibutramine—Alopecia—Doxorubicin—hematologic cancer	2.38e-05	4.81e-05	CcSEcCtD
Sibutramine—Paraesthesia—Prednisone—hematologic cancer	2.37e-05	4.8e-05	CcSEcCtD
Sibutramine—Pruritus—Triamcinolone—hematologic cancer	2.37e-05	4.79e-05	CcSEcCtD
Sibutramine—Cough—Methotrexate—hematologic cancer	2.36e-05	4.78e-05	CcSEcCtD
Sibutramine—Ill-defined disorder—Epirubicin—hematologic cancer	2.35e-05	4.75e-05	CcSEcCtD
Sibutramine—Convulsion—Methotrexate—hematologic cancer	2.35e-05	4.74e-05	CcSEcCtD
Sibutramine—Vomiting—Etoposide—hematologic cancer	2.35e-05	4.74e-05	CcSEcCtD
Sibutramine—Malnutrition—Doxorubicin—hematologic cancer	2.34e-05	4.74e-05	CcSEcCtD
Sibutramine—Anaemia—Epirubicin—hematologic cancer	2.34e-05	4.73e-05	CcSEcCtD
Sibutramine—Agitation—Epirubicin—hematologic cancer	2.33e-05	4.71e-05	CcSEcCtD
Sibutramine—Dyspepsia—Prednisone—hematologic cancer	2.33e-05	4.7e-05	CcSEcCtD
Sibutramine—Rash—Etoposide—hematologic cancer	2.33e-05	4.7e-05	CcSEcCtD
Sibutramine—Dermatitis—Etoposide—hematologic cancer	2.32e-05	4.7e-05	CcSEcCtD
Sibutramine—Headache—Etoposide—hematologic cancer	2.31e-05	4.67e-05	CcSEcCtD
Sibutramine—Flatulence—Doxorubicin—hematologic cancer	2.31e-05	4.67e-05	CcSEcCtD
Sibutramine—Chest pain—Methotrexate—hematologic cancer	2.3e-05	4.66e-05	CcSEcCtD
Sibutramine—Arthralgia—Methotrexate—hematologic cancer	2.3e-05	4.66e-05	CcSEcCtD
Sibutramine—Myalgia—Methotrexate—hematologic cancer	2.3e-05	4.66e-05	CcSEcCtD
Sibutramine—Tension—Doxorubicin—hematologic cancer	2.3e-05	4.65e-05	CcSEcCtD
Sibutramine—Decreased appetite—Prednisone—hematologic cancer	2.3e-05	4.65e-05	CcSEcCtD
Sibutramine—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	2.3e-05	0.000547	CbGpPWpGaD
Sibutramine—Dysgeusia—Doxorubicin—hematologic cancer	2.3e-05	4.64e-05	CcSEcCtD
Sibutramine—Rash—Prednisolone—hematologic cancer	2.29e-05	4.64e-05	CcSEcCtD
Sibutramine—Dermatitis—Prednisolone—hematologic cancer	2.29e-05	4.63e-05	CcSEcCtD
Sibutramine—Malaise—Epirubicin—hematologic cancer	2.28e-05	4.62e-05	CcSEcCtD
Sibutramine—Headache—Prednisolone—hematologic cancer	2.28e-05	4.61e-05	CcSEcCtD
Sibutramine—Discomfort—Methotrexate—hematologic cancer	2.28e-05	4.6e-05	CcSEcCtD
Sibutramine—Nervousness—Doxorubicin—hematologic cancer	2.28e-05	4.6e-05	CcSEcCtD
Sibutramine—Vertigo—Epirubicin—hematologic cancer	2.28e-05	4.6e-05	CcSEcCtD
Sibutramine—Syncope—Epirubicin—hematologic cancer	2.27e-05	4.59e-05	CcSEcCtD
Sibutramine—Leukopenia—Epirubicin—hematologic cancer	2.27e-05	4.58e-05	CcSEcCtD
Sibutramine—Back pain—Doxorubicin—hematologic cancer	2.27e-05	4.58e-05	CcSEcCtD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	2.27e-05	0.00054	CbGpPWpGaD
Sibutramine—Constipation—Prednisone—hematologic cancer	2.26e-05	4.57e-05	CcSEcCtD
Sibutramine—Muscle spasms—Doxorubicin—hematologic cancer	2.25e-05	4.56e-05	CcSEcCtD
Sibutramine—Palpitations—Epirubicin—hematologic cancer	2.24e-05	4.53e-05	CcSEcCtD
Sibutramine—Confusional state—Methotrexate—hematologic cancer	2.23e-05	4.5e-05	CcSEcCtD
Sibutramine—Loss of consciousness—Epirubicin—hematologic cancer	2.23e-05	4.5e-05	CcSEcCtD
Sibutramine—Dizziness—Triamcinolone—hematologic cancer	2.21e-05	4.47e-05	CcSEcCtD
Sibutramine—Cough—Epirubicin—hematologic cancer	2.21e-05	4.47e-05	CcSEcCtD
Sibutramine—Anaphylactic shock—Methotrexate—hematologic cancer	2.21e-05	4.47e-05	CcSEcCtD
Sibutramine—Vision blurred—Doxorubicin—hematologic cancer	2.21e-05	4.47e-05	CcSEcCtD
Sibutramine—Convulsion—Epirubicin—hematologic cancer	2.2e-05	4.44e-05	CcSEcCtD
Sibutramine—Infection—Methotrexate—hematologic cancer	2.2e-05	4.44e-05	CcSEcCtD
Sibutramine—Nausea—Etoposide—hematologic cancer	2.19e-05	4.43e-05	CcSEcCtD
Sibutramine—Hypertension—Epirubicin—hematologic cancer	2.19e-05	4.42e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Prednisone—hematologic cancer	2.18e-05	4.4e-05	CcSEcCtD
Sibutramine—Asthenia—Dexamethasone—hematologic cancer	2.18e-05	4.4e-05	CcSEcCtD
Sibutramine—Asthenia—Betamethasone—hematologic cancer	2.18e-05	4.4e-05	CcSEcCtD
Sibutramine—Ill-defined disorder—Doxorubicin—hematologic cancer	2.18e-05	4.4e-05	CcSEcCtD
Sibutramine—Anaemia—Doxorubicin—hematologic cancer	2.17e-05	4.38e-05	CcSEcCtD
Sibutramine—Thrombocytopenia—Methotrexate—hematologic cancer	2.16e-05	4.37e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Prednisone—hematologic cancer	2.16e-05	4.37e-05	CcSEcCtD
Sibutramine—Nausea—Prednisolone—hematologic cancer	2.16e-05	4.37e-05	CcSEcCtD
Sibutramine—Myalgia—Epirubicin—hematologic cancer	2.16e-05	4.36e-05	CcSEcCtD
Sibutramine—Arthralgia—Epirubicin—hematologic cancer	2.16e-05	4.36e-05	CcSEcCtD
Sibutramine—Chest pain—Epirubicin—hematologic cancer	2.16e-05	4.36e-05	CcSEcCtD
Sibutramine—Agitation—Doxorubicin—hematologic cancer	2.15e-05	4.35e-05	CcSEcCtD
Sibutramine—Anxiety—Epirubicin—hematologic cancer	2.15e-05	4.35e-05	CcSEcCtD
Sibutramine—Pruritus—Dexamethasone—hematologic cancer	2.15e-05	4.34e-05	CcSEcCtD
Sibutramine—Pruritus—Betamethasone—hematologic cancer	2.15e-05	4.34e-05	CcSEcCtD
Sibutramine—Skin disorder—Methotrexate—hematologic cancer	2.15e-05	4.34e-05	CcSEcCtD
Sibutramine—Hyperhidrosis—Methotrexate—hematologic cancer	2.14e-05	4.32e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—HRAS—hematologic cancer	2.13e-05	0.000508	CbGpPWpGaD
Sibutramine—Discomfort—Epirubicin—hematologic cancer	2.13e-05	4.31e-05	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.13e-05	0.000507	CbGpPWpGaD
Sibutramine—Vomiting—Triamcinolone—hematologic cancer	2.13e-05	4.3e-05	CcSEcCtD
Sibutramine—Malaise—Doxorubicin—hematologic cancer	2.11e-05	4.27e-05	CcSEcCtD
Sibutramine—Rash—Triamcinolone—hematologic cancer	2.11e-05	4.26e-05	CcSEcCtD
Sibutramine—Dry mouth—Epirubicin—hematologic cancer	2.11e-05	4.26e-05	CcSEcCtD
Sibutramine—Dermatitis—Triamcinolone—hematologic cancer	2.11e-05	4.26e-05	CcSEcCtD
Sibutramine—Vertigo—Doxorubicin—hematologic cancer	2.11e-05	4.26e-05	CcSEcCtD
Sibutramine—Anorexia—Methotrexate—hematologic cancer	2.11e-05	4.26e-05	CcSEcCtD
Sibutramine—Syncope—Doxorubicin—hematologic cancer	2.1e-05	4.25e-05	CcSEcCtD
Sibutramine—Urticaria—Prednisone—hematologic cancer	2.1e-05	4.25e-05	CcSEcCtD
Sibutramine—Leukopenia—Doxorubicin—hematologic cancer	2.1e-05	4.24e-05	CcSEcCtD
Sibutramine—Headache—Triamcinolone—hematologic cancer	2.1e-05	4.24e-05	CcSEcCtD
Sibutramine—Abdominal pain—Prednisone—hematologic cancer	2.09e-05	4.22e-05	CcSEcCtD
Sibutramine—Body temperature increased—Prednisone—hematologic cancer	2.09e-05	4.22e-05	CcSEcCtD
Sibutramine—Confusional state—Epirubicin—hematologic cancer	2.08e-05	4.21e-05	CcSEcCtD
Sibutramine—Diarrhoea—Dexamethasone—hematologic cancer	2.08e-05	4.2e-05	CcSEcCtD
Sibutramine—Diarrhoea—Betamethasone—hematologic cancer	2.08e-05	4.2e-05	CcSEcCtD
Sibutramine—Palpitations—Doxorubicin—hematologic cancer	2.07e-05	4.19e-05	CcSEcCtD
Sibutramine—Oedema—Epirubicin—hematologic cancer	2.07e-05	4.18e-05	CcSEcCtD
Sibutramine—Anaphylactic shock—Epirubicin—hematologic cancer	2.07e-05	4.18e-05	CcSEcCtD
Sibutramine—Hypotension—Methotrexate—hematologic cancer	2.06e-05	4.17e-05	CcSEcCtD
Sibutramine—Loss of consciousness—Doxorubicin—hematologic cancer	2.06e-05	4.17e-05	CcSEcCtD
Sibutramine—Infection—Epirubicin—hematologic cancer	2.05e-05	4.15e-05	CcSEcCtD
Sibutramine—Cough—Doxorubicin—hematologic cancer	2.05e-05	4.14e-05	CcSEcCtD
Sibutramine—Shock—Epirubicin—hematologic cancer	2.03e-05	4.11e-05	CcSEcCtD
Sibutramine—Convulsion—Doxorubicin—hematologic cancer	2.03e-05	4.11e-05	CcSEcCtD
Sibutramine—Thrombocytopenia—Epirubicin—hematologic cancer	2.02e-05	4.09e-05	CcSEcCtD
Sibutramine—Hypertension—Doxorubicin—hematologic cancer	2.02e-05	4.09e-05	CcSEcCtD
Sibutramine—Tachycardia—Epirubicin—hematologic cancer	2.02e-05	4.08e-05	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.01e-05	4.07e-05	CcSEcCtD
Sibutramine—Skin disorder—Epirubicin—hematologic cancer	2.01e-05	4.06e-05	CcSEcCtD
Sibutramine—Dizziness—Dexamethasone—hematologic cancer	2.01e-05	4.06e-05	CcSEcCtD
Sibutramine—Dizziness—Betamethasone—hematologic cancer	2.01e-05	4.06e-05	CcSEcCtD
Sibutramine—Hyperhidrosis—Epirubicin—hematologic cancer	2e-05	4.04e-05	CcSEcCtD
Sibutramine—Insomnia—Methotrexate—hematologic cancer	2e-05	4.04e-05	CcSEcCtD
Sibutramine—Myalgia—Doxorubicin—hematologic cancer	2e-05	4.03e-05	CcSEcCtD
Sibutramine—Arthralgia—Doxorubicin—hematologic cancer	2e-05	4.03e-05	CcSEcCtD
Sibutramine—Chest pain—Doxorubicin—hematologic cancer	2e-05	4.03e-05	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ALB—hematologic cancer	1.99e-05	0.000475	CbGpPWpGaD
Sibutramine—Anxiety—Doxorubicin—hematologic cancer	1.99e-05	4.02e-05	CcSEcCtD
Sibutramine—Nausea—Triamcinolone—hematologic cancer	1.99e-05	4.02e-05	CcSEcCtD
Sibutramine—Paraesthesia—Methotrexate—hematologic cancer	1.98e-05	4.01e-05	CcSEcCtD
Sibutramine—Discomfort—Doxorubicin—hematologic cancer	1.97e-05	3.99e-05	CcSEcCtD
Sibutramine—Anorexia—Epirubicin—hematologic cancer	1.97e-05	3.98e-05	CcSEcCtD
Sibutramine—Dyspnoea—Methotrexate—hematologic cancer	1.97e-05	3.98e-05	CcSEcCtD
Sibutramine—Somnolence—Methotrexate—hematologic cancer	1.96e-05	3.97e-05	CcSEcCtD
Sibutramine—Dry mouth—Doxorubicin—hematologic cancer	1.95e-05	3.95e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Prednisone—hematologic cancer	1.95e-05	3.94e-05	CcSEcCtD
Sibutramine—Dyspepsia—Methotrexate—hematologic cancer	1.94e-05	3.93e-05	CcSEcCtD
Sibutramine—Hypotension—Epirubicin—hematologic cancer	1.93e-05	3.91e-05	CcSEcCtD
Sibutramine—Vomiting—Dexamethasone—hematologic cancer	1.93e-05	3.9e-05	CcSEcCtD
Sibutramine—Vomiting—Betamethasone—hematologic cancer	1.93e-05	3.9e-05	CcSEcCtD
Sibutramine—Confusional state—Doxorubicin—hematologic cancer	1.93e-05	3.9e-05	CcSEcCtD
Sibutramine—Decreased appetite—Methotrexate—hematologic cancer	1.92e-05	3.88e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—GMPS—hematologic cancer	1.92e-05	0.000456	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PHYH—hematologic cancer	1.92e-05	0.000456	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—FTCD—hematologic cancer	1.92e-05	0.000456	CbGpPWpGaD
Sibutramine—Rash—Betamethasone—hematologic cancer	1.91e-05	3.87e-05	CcSEcCtD
Sibutramine—Rash—Dexamethasone—hematologic cancer	1.91e-05	3.87e-05	CcSEcCtD
Sibutramine—Anaphylactic shock—Doxorubicin—hematologic cancer	1.91e-05	3.87e-05	CcSEcCtD
Sibutramine—Oedema—Doxorubicin—hematologic cancer	1.91e-05	3.87e-05	CcSEcCtD
Sibutramine—Dermatitis—Betamethasone—hematologic cancer	1.91e-05	3.87e-05	CcSEcCtD
Sibutramine—Dermatitis—Dexamethasone—hematologic cancer	1.91e-05	3.87e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.91e-05	3.86e-05	CcSEcCtD
Sibutramine—Headache—Dexamethasone—hematologic cancer	1.9e-05	3.84e-05	CcSEcCtD
Sibutramine—Headache—Betamethasone—hematologic cancer	1.9e-05	3.84e-05	CcSEcCtD
Sibutramine—Infection—Doxorubicin—hematologic cancer	1.9e-05	3.84e-05	CcSEcCtD
Sibutramine—Asthenia—Prednisone—hematologic cancer	1.9e-05	3.83e-05	CcSEcCtD
Sibutramine—Pain—Methotrexate—hematologic cancer	1.89e-05	3.82e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.89e-05	0.000449	CbGpPWpGaD
Sibutramine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.88e-05	3.81e-05	CcSEcCtD
Sibutramine—Shock—Doxorubicin—hematologic cancer	1.88e-05	3.81e-05	CcSEcCtD
Sibutramine—Thrombocytopenia—Doxorubicin—hematologic cancer	1.87e-05	3.79e-05	CcSEcCtD
Sibutramine—Pruritus—Prednisone—hematologic cancer	1.87e-05	3.78e-05	CcSEcCtD
Sibutramine—Insomnia—Epirubicin—hematologic cancer	1.87e-05	3.78e-05	CcSEcCtD
Sibutramine—Tachycardia—Doxorubicin—hematologic cancer	1.87e-05	3.77e-05	CcSEcCtD
Sibutramine—Skin disorder—Doxorubicin—hematologic cancer	1.86e-05	3.76e-05	CcSEcCtD
Sibutramine—Paraesthesia—Epirubicin—hematologic cancer	1.86e-05	3.75e-05	CcSEcCtD
Sibutramine—Hyperhidrosis—Doxorubicin—hematologic cancer	1.85e-05	3.74e-05	CcSEcCtD
Sibutramine—Dyspnoea—Epirubicin—hematologic cancer	1.84e-05	3.73e-05	CcSEcCtD
Sibutramine—Somnolence—Epirubicin—hematologic cancer	1.84e-05	3.72e-05	CcSEcCtD
Sibutramine—Anorexia—Doxorubicin—hematologic cancer	1.82e-05	3.69e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Methotrexate—hematologic cancer	1.82e-05	3.68e-05	CcSEcCtD
Sibutramine—Dyspepsia—Epirubicin—hematologic cancer	1.82e-05	3.68e-05	CcSEcCtD
Sibutramine—Diarrhoea—Prednisone—hematologic cancer	1.81e-05	3.66e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.81e-05	3.65e-05	CcSEcCtD
Sibutramine—Nausea—Betamethasone—hematologic cancer	1.8e-05	3.65e-05	CcSEcCtD
Sibutramine—Nausea—Dexamethasone—hematologic cancer	1.8e-05	3.65e-05	CcSEcCtD
Sibutramine—Decreased appetite—Epirubicin—hematologic cancer	1.8e-05	3.63e-05	CcSEcCtD
Sibutramine—Hypotension—Doxorubicin—hematologic cancer	1.79e-05	3.61e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.79e-05	3.61e-05	CcSEcCtD
Sibutramine—Pain—Epirubicin—hematologic cancer	1.77e-05	3.57e-05	CcSEcCtD
Sibutramine—Constipation—Epirubicin—hematologic cancer	1.77e-05	3.57e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ALB—hematologic cancer	1.76e-05	0.00042	CbGpPWpGaD
Sibutramine—Urticaria—Methotrexate—hematologic cancer	1.76e-05	3.55e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.75e-05	0.000417	CbGpPWpGaD
Sibutramine—Dizziness—Prednisone—hematologic cancer	1.75e-05	3.53e-05	CcSEcCtD
Sibutramine—Abdominal pain—Methotrexate—hematologic cancer	1.75e-05	3.53e-05	CcSEcCtD
Sibutramine—Body temperature increased—Methotrexate—hematologic cancer	1.75e-05	3.53e-05	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.74e-05	3.52e-05	CcSEcCtD
Sibutramine—Insomnia—Doxorubicin—hematologic cancer	1.73e-05	3.5e-05	CcSEcCtD
Sibutramine—Paraesthesia—Doxorubicin—hematologic cancer	1.72e-05	3.47e-05	CcSEcCtD
Sibutramine—Dyspnoea—Doxorubicin—hematologic cancer	1.71e-05	3.45e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Epirubicin—hematologic cancer	1.7e-05	3.44e-05	CcSEcCtD
Sibutramine—Somnolence—Doxorubicin—hematologic cancer	1.7e-05	3.44e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.69e-05	3.42e-05	CcSEcCtD
Sibutramine—Dyspepsia—Doxorubicin—hematologic cancer	1.68e-05	3.4e-05	CcSEcCtD
Sibutramine—Vomiting—Prednisone—hematologic cancer	1.68e-05	3.4e-05	CcSEcCtD
Sibutramine—Rash—Prednisone—hematologic cancer	1.67e-05	3.37e-05	CcSEcCtD
Sibutramine—Dermatitis—Prednisone—hematologic cancer	1.67e-05	3.37e-05	CcSEcCtD
Sibutramine—Decreased appetite—Doxorubicin—hematologic cancer	1.66e-05	3.36e-05	CcSEcCtD
Sibutramine—Headache—Prednisone—hematologic cancer	1.66e-05	3.35e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.65e-05	3.34e-05	CcSEcCtD
Sibutramine—Urticaria—Epirubicin—hematologic cancer	1.64e-05	3.32e-05	CcSEcCtD
Sibutramine—Pain—Doxorubicin—hematologic cancer	1.64e-05	3.31e-05	CcSEcCtD
Sibutramine—Constipation—Doxorubicin—hematologic cancer	1.64e-05	3.31e-05	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—HRAS—hematologic cancer	1.63e-05	0.000389	CbGpPWpGaD
Sibutramine—Abdominal pain—Epirubicin—hematologic cancer	1.63e-05	3.3e-05	CcSEcCtD
Sibutramine—Body temperature increased—Epirubicin—hematologic cancer	1.63e-05	3.3e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Methotrexate—hematologic cancer	1.63e-05	3.29e-05	CcSEcCtD
Sibutramine—Asthenia—Methotrexate—hematologic cancer	1.59e-05	3.2e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Doxorubicin—hematologic cancer	1.58e-05	3.19e-05	CcSEcCtD
Sibutramine—Nausea—Prednisone—hematologic cancer	1.57e-05	3.17e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.56e-05	3.16e-05	CcSEcCtD
Sibutramine—Pruritus—Methotrexate—hematologic cancer	1.56e-05	3.16e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—ASNS—hematologic cancer	1.53e-05	0.000365	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—DCK—hematologic cancer	1.53e-05	0.000365	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.53e-05	0.000365	CbGpPWpGaD
Sibutramine—Hypersensitivity—Epirubicin—hematologic cancer	1.52e-05	3.08e-05	CcSEcCtD
Sibutramine—Urticaria—Doxorubicin—hematologic cancer	1.52e-05	3.07e-05	CcSEcCtD
Sibutramine—Abdominal pain—Doxorubicin—hematologic cancer	1.51e-05	3.06e-05	CcSEcCtD
Sibutramine—Body temperature increased—Doxorubicin—hematologic cancer	1.51e-05	3.06e-05	CcSEcCtD
Sibutramine—Diarrhoea—Methotrexate—hematologic cancer	1.51e-05	3.06e-05	CcSEcCtD
Sibutramine—Asthenia—Epirubicin—hematologic cancer	1.48e-05	3e-05	CcSEcCtD
Sibutramine—Pruritus—Epirubicin—hematologic cancer	1.46e-05	2.96e-05	CcSEcCtD
Sibutramine—Dizziness—Methotrexate—hematologic cancer	1.46e-05	2.95e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—HDC—hematologic cancer	1.45e-05	0.000346	CbGpPWpGaD
Sibutramine—Diarrhoea—Epirubicin—hematologic cancer	1.41e-05	2.86e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Doxorubicin—hematologic cancer	1.41e-05	2.85e-05	CcSEcCtD
Sibutramine—Vomiting—Methotrexate—hematologic cancer	1.4e-05	2.84e-05	CcSEcCtD
Sibutramine—Rash—Methotrexate—hematologic cancer	1.39e-05	2.82e-05	CcSEcCtD
Sibutramine—Dermatitis—Methotrexate—hematologic cancer	1.39e-05	2.81e-05	CcSEcCtD
Sibutramine—Headache—Methotrexate—hematologic cancer	1.38e-05	2.8e-05	CcSEcCtD
Sibutramine—Asthenia—Doxorubicin—hematologic cancer	1.37e-05	2.77e-05	CcSEcCtD
Sibutramine—Dizziness—Epirubicin—hematologic cancer	1.37e-05	2.76e-05	CcSEcCtD
Sibutramine—Pruritus—Doxorubicin—hematologic cancer	1.35e-05	2.74e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—CDA—hematologic cancer	1.33e-05	0.000316	CbGpPWpGaD
Sibutramine—Vomiting—Epirubicin—hematologic cancer	1.31e-05	2.66e-05	CcSEcCtD
Sibutramine—Nausea—Methotrexate—hematologic cancer	1.31e-05	2.65e-05	CcSEcCtD
Sibutramine—Diarrhoea—Doxorubicin—hematologic cancer	1.31e-05	2.65e-05	CcSEcCtD
Sibutramine—Rash—Epirubicin—hematologic cancer	1.3e-05	2.64e-05	CcSEcCtD
Sibutramine—Dermatitis—Epirubicin—hematologic cancer	1.3e-05	2.63e-05	CcSEcCtD
Sibutramine—Headache—Epirubicin—hematologic cancer	1.3e-05	2.62e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—PC—hematologic cancer	1.28e-05	0.000304	CbGpPWpGaD
Sibutramine—Dizziness—Doxorubicin—hematologic cancer	1.27e-05	2.56e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.23e-05	0.000294	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GBA—hematologic cancer	1.23e-05	0.000294	CbGpPWpGaD
Sibutramine—Nausea—Epirubicin—hematologic cancer	1.23e-05	2.48e-05	CcSEcCtD
Sibutramine—Vomiting—Doxorubicin—hematologic cancer	1.22e-05	2.46e-05	CcSEcCtD
Sibutramine—Rash—Doxorubicin—hematologic cancer	1.21e-05	2.44e-05	CcSEcCtD
Sibutramine—Dermatitis—Doxorubicin—hematologic cancer	1.21e-05	2.44e-05	CcSEcCtD
Sibutramine—Headache—Doxorubicin—hematologic cancer	1.2e-05	2.42e-05	CcSEcCtD
Sibutramine—Nausea—Doxorubicin—hematologic cancer	1.14e-05	2.3e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—MTAP—hematologic cancer	1.13e-05	0.000269	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—FHL2—hematologic cancer	1.01e-05	0.00024	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AGRN—hematologic cancer	9.87e-06	0.000235	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—IDH2—hematologic cancer	9.35e-06	0.000223	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMMR—hematologic cancer	9.35e-06	0.000223	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ARNTL—hematologic cancer	8.8e-06	0.00021	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CA9—hematologic cancer	8.56e-06	0.000204	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ACP5—hematologic cancer	8.56e-06	0.000204	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NCOR2—hematologic cancer	8.44e-06	0.000201	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—IDH1—hematologic cancer	8.04e-06	0.000192	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCC3—hematologic cancer	7.95e-06	0.000189	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTO1—hematologic cancer	7.95e-06	0.000189	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TXN—hematologic cancer	7.95e-06	0.000189	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SPHK1—hematologic cancer	7.78e-06	0.000185	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	7.48e-06	0.000178	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CRABP1—hematologic cancer	7.28e-06	0.000173	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	7.28e-06	0.000173	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALOX5—hematologic cancer	7.09e-06	0.000169	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NUP98—hematologic cancer	6.87e-06	0.000164	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADCY7—hematologic cancer	6.67e-06	0.000159	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NCOA3—hematologic cancer	6.67e-06	0.000159	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NUP214—hematologic cancer	6.62e-06	0.000158	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCG2—hematologic cancer	6.48e-06	0.000154	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MTR—hematologic cancer	6.48e-06	0.000154	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ENO2—hematologic cancer	6.36e-06	0.000151	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.17e-06	0.000147	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SDC1—hematologic cancer	6.03e-06	0.000144	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CD44—hematologic cancer	5.13e-06	0.000122	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NQO1—hematologic cancer	5.13e-06	0.000122	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYCS—hematologic cancer	4.85e-06	0.000116	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.82e-06	0.000115	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.28e-06	0.000102	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.05e-06	9.64e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.93e-06	9.36e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.93e-06	9.36e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.47e-06	8.27e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.92e-06	6.95e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.7e-06	6.44e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.56e-06	6.11e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALB—hematologic cancer	2.53e-06	6.03e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.42e-06	5.77e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.24e-06	5.32e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTEN—hematologic cancer	1.93e-06	4.6e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—EP300—hematologic cancer	1.84e-06	4.39e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.36e-06	3.25e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AKT1—hematologic cancer	1.11e-06	2.65e-05	CbGpPWpGaD
